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Background: The traditional Chinese medicine classic herbal formula Longdanxiegan
decoction (LDXGD) is widely used for hypertensive patients in China.
Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy
and safety of LDXGD for hypertension.
Methods: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Chinese
Biomedical Literature Database, Chinese Scientific Journal Database, Chinese National
Knowledge Infrastructure, andWanfang Database were searched up to February 7, 2017
for randomized control trials in treating hypertension.
Results: Nine trials were identified. Compared with antihypertensive drugs,
Longdanxiegan decoction plus antihypertensive drugs (LPAD) significantly improved
systolic blood pressure (BP) (n = 138; MD = −4.82 mmHg; 95% CI: −7.89 to
−1.76; P = 0.002), diastolic BP (n = 138; MD = −2.42 mmHg; 95% CI: −3.22 to
−1.62; P < 0.00001), categorical BP (n = 509; RR: 1.26; 95% CI: 1.17 to 1.36;
P < 0.00001), hypertension related symptoms (n = 509; RR: 1.31; 95% CI: 1.15 to
1.49; P < 0.0001), and heart rate (n= 138; MD=−2.40 bpm; 95% CI:−4.23 to−0.56;
P = 0.01). Beneficial effects but no statistically significant reduction in total cholesterol
(n = 138; MD = −0.11 mmol/l; 95% CI: −0.65 to 0.44; P = 0.71), or triglyceride
(n = 138; MD = −0.20 mmol/l; 95% CI: −0.46 to 0.07; P = 0.14) was observed in
LPAD. Compared with antihypertensive drugs, LDXGD used alone significantly improved
systolic BP, diastolic BP, and hypertension related symptoms. But there was no
difference between LDXGD and antihypertensive drugs on categorical BP (n = 120;
RR: 1.09; 95% CI: 0.96 to 1.23; P = 0.18). The safety of LDXGD were still unclear.
Xiong et al. Longdanxiegan Decoction for Hypertension
Conclusions: Due to poor methodological quality of the included trials, as well as
potential reporting bias, our review found no conclusive evidence for the effectiveness
of LDXGD in treating hypertension. The potential beneficial effects and safety of LDXGD
should be assessed in future properly designed trials.
Keywords: hypertension, blood pressure, traditional Chinese medicine, classic herbal formula, Longdanxiegan
decoction, systematic review
INTRODUCTION
Cardiovascular diseases continue to represent the major cause
of death worldwide. Hypertension is a major contributor to
cardiovascular diseases, cerebrovascular disease, and renal failure
(James et al., 2014). A strong association between hypertension
and cardiovascular diseases has been established by numerous
epidemiological studies. Over the past 2 decades, abundant
evidence from randomized controlled trials (RCTs) identified
that the current awareness, curative, and control rates of
hypertension have been improved; however, they remain far
from ideal (Unger, 2014). Thus, some hypertensive patients have
turned to traditional Chinese medicine (TCM) for seeking new
antihypertensive modalities with fewer adverse effects in East
Asia (Xiong et al., 2013a).
TCM classic herbal formula is defined as a formula that
has been recorded in ancient TCM classic medical books
with fixed herbal drug composition, definite curative effect,
and fewer adverse effects for certain diseases (Xiong et al.,
2017a). Recently, more robust evidence from meta-analyses and
systematic reviews have showed improvements in blood pressure
(BP) and hypertension related symptoms by TCM classic herbal
formulas, including Banxia baizhu tianma decoction (Xiong
et al., 2012), Tianma gouteng yin (Wang et al., 2013), Zhen
gan xi feng decoction (Xiong et al., 2013b), Jian ling decoction
(Xiong et al., 2015a), Liu wei di huang wan (Wang et al.,
2012), Shenqi pill (Xiong et al., 2015b), Zhen wu decoction
(Xiong et al., 2015c), and Xuefu zhuyu decoction (Wang et al.,
2015). Longdanxiegan decoction (LDXGD) is one of the most
utilized TCM classic herbal formula invented by Ang Wang in Yi
Fang Ji Jie (Variorum of Medical Recipes) in the Qing Dynasty.
According to TCM theory, liver-yang hyperactivity syndrome
and liver damp-heat syndrome are 2 most common patterns
of hypertension, which often appear simultaneously (Wang and
Xiong, 2012). Interestingly, LDXGD possesses the efficacy of
calming the liver-yang and clearing away liver damp-heat, which
could obviously improve the liver-yang hyperactivity and liver
damp-heat syndromes in TCM theory. Such pharmacological
effects of LDXGD amount to inhibition of sympathetic activity
from the perspective of modern science. LDXGD is composed
by the following 10 Chinese herbal medicines, including Chinese
Gentian Root (Longdancao, Radix Gentianae Longdancao),
Gardenia (Zhizi, Fructus Gardeniae Jasminoidis), Baical Skullcap
Root (Huangqin, Radix Scutellariae Baicalensis), Thorowax
Root (Chaihu, Radix Bupleuri), Rehmannia (Dihuang, Radix
Rehmanniae Glutinosae), Plantain Seed (Cheqianzi, Semen
Plantaginis), Alisma (Zexie, Rhizoma Alismatis), Akebia Stem
(Mutong, Caulis Akebiae), Chinese Angelica Root (Danggui,
Radix Angelicae Sinensis), and Liquoric Root (Gancao, Radix
Glycyrrhizae). The main chemical components of LDXGD
included gentiopicrin, gardenoside, baicalin, rehmannioside,
plantaginin, alisol A monoacetate, angelica polysaccharide, etc
(Wang et al., 2007). Currently, it has been widely used to treat
numerous diseases including acute cholecystitis, non-alcoholic
fatty liver disease (Yu and Zhang, 2017), hyperthyroidism (Lei
and Wei, 2017), acute posterior ganglionitis (Wang and Wang,
2016), acute epididymitis (Pan et al., 2016), drug hepatitis (Zhu,
2016), hypertension (Lv, 2007), etc.
In recent years, LDXGDhas been widely prescribed in treating
hypertension by TCM physicians in China. The indications of
LDXGD for hypertensive patients included vertigo, headache,
facial flushing with perspiration, conjunctival congestion, bitter
taste in the mouth, thirst, irritability and restlessness, red
tongue with yellow greasy fur, wiry-rapid-powerful pulse or
powerful cunkou pulse alone, or wiry and long pulse even well-
beyond the cunkou pulse. This prescription can be used as
long as it meets the above indications regardless of the level
and risk stratification of hypertension by western medicine.
Numerous clinical studies ranged from case reports, case series
to RCTs also suggested that LDXGD might be effective in
lowering BP and relieving hypertension related symptoms (Yang,
2013; Shi, 2014; Wang, 2014). However, the clinical benefit of
LDXGD for hypertension still remains uncertain due to limited
sample size, inconsistent trial design, and unclear methodological
quality of the published clinical trials. Therefore, we conducted
this systematic review and meta-analysis for the following
purposes: (a) to examine the efficacy of LDXGD vs. placebo,
no intervention, or antihypertensive drugs; (b) to examine the
effectiveness of LDXGD plus antihypertensive drugs (LPAD) vs.
antihypertensive drugs used alone; and (c) to examine the safety
of LDXGD.
METHODS
This systematic review and meta-analysis was performed in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines (Liberati et al.,
2009).
Search Strategies for Identification of
Studies
We searched PubMed, EMBASE, Cochrane Central Register of
Controlled Trials, Chinese Biomedical Literature Database,
Chinese Scientific Journal Database, Chinese National
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Knowledge Infrastructure, and Wanfang Database from
their inceptions to February 7, 2017 to identify RCTs that
examined the efficacy of LDXGD on hypertension. We used the
following keywords for databases searching: (“hypertension” OR
“essential hypertension” OR “primary hypertension” OR “high
blood pressure” OR “blood pressure” OR “gao xue ya”) AND
(“Longdanxiegan decoction” OR “Longdanxiegan tang” OR
“Longdanxiegantang”) AND (“clinical trial” OR “randomized
controlled trial” OR “randomized controlled trial” OR “lin
chuang yan jiu”). Reference of important articles were searched
manually for possible relevant studies. No restriction on
publication status or language was preestablished.
Inclusion Criteria
Only RCTs that met the following criteria could be enrolled
in this review: (a) the trial evaluated the efficacy of LDXGD
for hypertension; (b) patients were diagnosed by essential
hypertension based on the diagnostic criteria of Chinese
Guidelines for the Management of Hypertension, Guidelines
of Clinical Research of New Drugs of Traditional Chinese
Medicine, WHO-ISH Guidelines for the Management of
Hypertension, The seventh report of the Joint National
Committee on Prevention, Detection, Evaluation and Treatment
of high blood pressure (JNC 7), and other international
standards; (c) LDXGD was the only active intervention in the
treatment group compared with a control group, including
placebo, no intervention, and antihypertensive drugs; (d) RCTs
compared LPAD with antihypertensive drugs used alone; (e)
in studies comparing LPAD with antihypertensive drugs, the
type, specifications, and dosage of antihypertensive drugs used
in the treatment groups were the same as used in the control
groups; (f) the primary outcome measure was defined as BP,
including systolic blood pressure (SBP), diastolic blood pressure
(DBP), and categorical BP; and (f) the secondary outcome
measures were defined as mortality, progression to severe
complications, symptoms, heart rate (HR), total cholesterol
(TC), and triglycerides (TG). Severe complications were
defined as coronary heart disease, acute myocardial infarction,
heart failure, acute cerebrovascular disease, hypertensive renal
damage, and retinopathy due to high BP level. Hypertension
related symptoms recommended by China Food and Drug
Administration included vertigo, headache, etc. No limitation
on gender, age, or ethnic origin was provided. As the
rapidly antihypertensive effect of LDXGD was emphasized
in some studies, no restrictions on treatment duration was
preestablished.
Exclusion Criteria
If the following conditions were identified, the study should
be excluded: (a) studies were were not randomized or did not
adopt a control arm; (b) patients were diagnosed as secondary
hypertension, including renal hypertension, cushing syndrome,
primary aldosteronism, pheochromocytoma, and abdominal
aortic banding; (c) other interventions including qigong,
yoga, Tai Chi, Baduanjin, acupuncture, cupping, moxibustion,
massage, and blood-letting therapy were utilized in either
treatment or control group; and (d) no data on BP was
reported.
Data Extraction
The data was independently extracted by two reviewers (WL
and LD) according to the predesigned inclusion and exclusion
criteria. If disagreement was identified, it was resolved by
discussion with the third party (XKL and SHW). The following
data was extracted from the original research: first author’s
name, title, publication year, sample size, age, sex distribution,
diagnostic criteria, study design, methods used to generate the
randomization, level of blinding, explanation for withdrawal
or dropout, intervention methods, composition of LDXGD or
modified LDXGD, treatment duration, outcome measures, and
adverse effects.We also contacted the original authors formissing
information about the studies by emails, Telephone, or fax.
Risk of Bias Assessment
Two reviewers (PQW and HY) independently evaluated the
risk of bias of the included individual study according to the
Cochrane Handbook for Systematic Reviews of Interventions
(Higgins and Green, 2011). If missing data about the study
design was identified, the corresponding authors were contacted
through telephone, email, or fax contained in either original
research or published protocol. The following 7 aspects were
evaluated: (a) random sequence generation (selection bias);
(b) allocation concealment (selection bias); (c) blinding of
participants and personnel (performance bias); (d) blinding of
outcome assessment (detection bias); (e) incomplete outcome
data (attrition bias); (f) selective reporting (reporting bias); and
(g) other sources of bias (from Chapter 8: assessing risk of bias
in included studies). Judgments of each item were categorized
as “low risk of bias,” “high risk of bias,” or “unclear risk of bias”
according to the above criteria. Any discrepancy was resolved by
the third party (XKL and SHW).
Data Synthesis and Analysis
Review Manager software (RevMan, Version 5.3, Copenhagen:
The Nordic Cochrane Centre, Copenhagen, Denmark, The
Cochrane Collaboration, 2014) was utilized for data synthesis and
analysis. For continuous outcomes, they were presented as mean
difference (MD) between intervention and control groups with
95% confidence interval. And for dichotomous data, they were
presented as relative risk (RR) with 95% confidence interval. In
this meta-analysis, SBP, DBP, HR, TC, and TG were presented as
MD, while categorical BP, symptoms, and adverse effects as RR.
The random-effects model rather than the fixed-effects model
was used because the heterogeneity between multi-studies has
to be taken into account. P < 0.05 was considered to be of
statistically significance.
RESULTS
Study Identification
According to our search strategy in 7 electronic databases, 165
potential relevant publications were searched, of which 34 were
retrieved for further assessment, and 25 were excluded for the
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reasons listed in Figure 1. Finally, 9 eligible studies met the
inclusion criteria and were included (Yu and Ma, 2004; He and
Wang, 2010; Ye, 2013; Cao et al., 2014; Chen et al., 2014; Li, 2014,
2015; Xu, 2014; Ma, 2015).
Study Characteristics
The detailed information of basic characteristics was summarized
in Table 1. All of the 9 studies included were single-centered,
randomized, parallel, controlled clinical trials conducted in
China and published in Chinese language. No cross-over design
was applied. A total of 863 patients with hypertension were
enrolled in the review, with the sample size ranged from 42 to
241. All trials evaluated the efficacy of LDXGD used alone or
LPAD compared with antihypertensive drugs in hypertension
treatment. Patients in the treatment groups were treated by
LDXGD alone or LPAD. The components of LDXGD or
modified LDXGD were depicted in Table 2. Patients in the
control groups were treated by antihypertensive drugs alone.
Treatment duration ranged from 3 days to 12 weeks. BP data
was reported in all trials. The primary outcome measure on
SBP and DBP were reported in 3 trials (Ye, 2013; Li, 2014,
2015), while categorical BP was reported in 6 trials (Yu and
Ma, 2004; He and Wang, 2010; Cao et al., 2014; Chen et al.,
2014; Xu, 2014; Ma, 2015). The secondary outcome measures
were also reported. Among them, the symptoms were reported
in 6 trials (Yu and Ma, 2004; He and Wang, 2010; Cao
et al., 2014; Chen et al., 2014; Xu, 2014; Ma, 2015), while
HR, TC, and TG were reported in 2 trials (Ye, 2013; Li,
2015).
Risk of Bias
The risk of bias was assessed based on evaluation criterion
in the Cochrane handbook. Generally, methodological quality
of the included trials was assessed to be low. All of the
included trials declared randomization; however, no concrete
methods used to generate the allocation sequence and allocation
concealment were reported. None of the trials blinded the
participants, personnel, and assessor. No detailed description
on drop-out and withdrawal was reported. Because no protocol
of trials could be obtained from the primary authors, the
item of selective reporting could not be evaluated. The pre-
trial estimation of sample size was not applied. We tried to
contact the correspondence author for further information of the
study by email or telephone; however, none have replied to our
questions.
FIGURE 1 | Flow diagram of study selection and identification.
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TABLE 2 | Components of Chinese herbal formulas used in the included trials.
References Formula Components
Ye, 2013 LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 15 g, Gardenia (Zhizi, Fructus Gardeniae
Jasminoidis) 15 g, Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis) 10 g, Plantain Seed (Cheqianzi,
Semen Plantaginis) 10 g, Akebia Stem (Mutong, Caulis Akebiae) 10 g, Alisma (Zexie, Rhizoma Alismatis) 10 g,
Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 10 g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis)
5 g, Thorowax Root (Chaihu, Radix Bupleuri) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 5 g.
Li, 2015 LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 15 g, Gardenia (Zhizi, Fructus Gardeniae
Jasminoidis) 15 g, Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis) 10 g, Plantain Seed (Cheqianzi,
Semen Plantaginis) 10 g, Akebia Stem (Mutong, Caulis Akebiae) 10 g, Alisma (Zexie, Rhizoma Alismatis) 10 g,
Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 10 g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis)
5 g, Thorowax Root (Chaihu, Radix Bupleuri) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 5 g.
Chen et al., 2014 modified LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao), Gardenia (Zhizi, Fructus Gardeniae Jasminoidis),
Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis), Thorowax Root (Chaihu, Radix Bupleuri), Rehmannia
(Dihuang, Radix Rehmanniae Glutinosae), Plantain Seed (Cheqianzi, Semen Plantaginis), Alisma (Zexie, Rhizoma
Alismatis), Akebia Stem (Mutong, Caulis Akebiae), Liquoric Root (Gancao, Radix Glycyrrhizae), Chinese Angelica Root
(Danggui, Radix Angelicae Sinensis), Gastrodia (Tianma, Gastrodiae Rhizoma), Gambir Vine Stems and Thorns
(Gouteng, Ramulus Uncariae Cum Uncis), Abalone Shell (Shijueming, Haliotidis Concha), Eucommia Bark (Duzhong,
Cortex Eucommiae Ulmoidis), Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix), Chinese Taxillus Twig
(Sangjisheng, Herba Taxilli), Poria (Fuling, Scierotium Poriae Cocos), and Flowey Knotweed Stem (Yejiaoteng, Polygoni
Multiflori Caulis). If constipation was identifed, Magnolia Bark (Houpu, Cortex Magnoliae Officinalis), Immature Bitter
Orange (Zhishi, Fructus Citri Seu Ponciri Immaturus), Rhubarb Root and Rhizome (Dahuang, Radix Et Rhizoma Rhei),
and Sodium Sulfate Powder (Mangxiao, Natrii Sulfas Exsiccatus) were added. If severe vertigo was identified,
Fossilized Mammal Bones (Longgu, Os Draconis) and Oyster Shell (Muli, Concha Ostreae) were added. If hypertnesion
or unstable blood pressure was identifed, Antelope Horn (Lingyangjiao, Cornu Saigae Tataricae) was added.
Cao et al., 2014 modified LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 30 g, Gardenia (Zhizi, Fructus Gardeniae
Jasminoidis) 15 g, Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis) 15 g, Ricepaperplant Pith (Tongcao,
Medulla Tetrapanacis) 15 g, Alisma (Zexie, Rhizoma Alismatis) 15 g, Plantain Herb (Cheqiancao, Herba Plantaginis)
15 g, Thorowax Root (Chaihu, Radix Bupleuri) 30 g, Liquoric Root (Gancao, Radix Glycyrrhizae) 15 g, Chinese Angelica
Root (Danggui, Radix Angelicae Sinensis) 15 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 30 g, Achyranthes
Root (Niuxi, Achyranthis Bidentatae Radix) 30 g, Earthworm (Dilong, Lumbricus) 15 g, Prunella (Xiakucao, Spica
Prunellae Vulgaris) 15 g, and Seaweed (Haizao, Sargassum) 15 g.
Xu, 2014 LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 15 g, Baical Skullcap Root (Huangqin, Radix
Scutellariae Baicalensis) 19 g, Gardenia (Zhizi, Fructus Gardeniae Jasminoidis) 10 g, Alisma (Zexie, Rhizoma Alismatis)
20 g, Akebia Stem (Mutong, Caulis Akebiae) 10 g, Plantain Seed (Cheqianzi, Semen Plantaginis) 10 g, Chinese Angelica
Root (Danggui, Radix Angelicae Sinensis) 12 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 20 g, Thorowax
Root (Chaihu, Radix Bupleuri) 10 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 10 g.
Ma, 2015 modified LDXGD Baical Skullcap Root (Huangqin, Radix Scutellariae Baicalensis) 15 g, Gardenia (Zhizi, Fructus Gardeniae Jasminoidis)
15 g, Thorowax Root (Chaihu, Radix Bupleuri) 15 g, Alisma (Zexie, Rhizoma Alismatis) 15 g, Plantain Herb (Cheqiancao,
Herba Plantaginis) 15 g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 15 g, Prunella (Xiakucao, Spica
Prunellae Vulgaris) 15 g, Ricepaperplant Pith (Tongcao, Medulla Tetrapanacis) 15 g, Seaweed (Haizao, Sargassum)
15 g, Earthworm (Dilong, Lumbricus) 15 g, Liquoric Root (Gancao, Radix Glycyrrhizae) 15 g, Rehmannia (Dihuang,
Radix Rehmanniae Glutinosae) 30 g, Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 30 g, and
Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 30 g.
Li, 2014 LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 15 g, Gardenia (Zhizi, Fructus Gardeniae
Jasminoidis) 15 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 10 g, Baical Skullcap Root (Huangqin, Radix
Scutellariae Baicalensis) 10 g, Thorowax Root (Chaihu, Radix Bupleuri) 10 g, Plantain Seed (Cheqianzi, Semen
Plantaginis) 10 g, Alisma (Zexie, Rhizoma Alismatis) 10 g, Akebia Stem (Mutong, Caulis Akebiae) 10 g, Chinese Angelica
Root (Danggui, Radix Angelicae Sinensis) 5 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 5 g.
Yu and Ma, 2004 modified LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 15 g, Plantain Seed (Cheqianzi, Semen
Plantaginis) 30 g, Alisma (Zexie, Rhizoma Alismatis) 30 g, Rehmannia (Dihuang, Radix Rehmanniae Glutinosae) 15 g,
Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 10 g, Akebia Stem (Mutong, Caulis Akebiae) 15 g,
Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 15 g, Earthworm (Dilong, Lumbricus) 10 g, Prunella (Xiakucao,
Spica Prunellae Vulgaris) 30 g, and Seaweed (Haizao, Sargassum) 15 g.
(Continued)
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TABLE 2 | Continued
References Formula Components
He and Wang, 2010 LDXGD Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 9 g, Baical Skullcap Root (Huangqin, Radix
Scutellariae Baicalensis) 12 g, Gardenia (Zhizi, Fructus Gardeniae Jasminoidis) 12 g, Thorowax Root (Chaihu, Radix
Bupleuri) 9 g, Alisma (Zexie, Rhizoma Alismatis) 12 g, Plantain Seed (Cheqianzi, Semen Plantaginis) 9 g, Rehmannia
(Dihuang, Radix Rehmanniae Glutinosae) 9 g, Akebia Stem (Mutong, Caulis Akebiae) 9 g, Chinese Angelica Root
(Danggui, Radix Angelicae Sinensis) 6 g, and Liquoric Root (Gancao, Radix Glycyrrhizae) 6 g. If severe headache and
vertigo were identified, Prunella (Xiakucao, Spica Prunellae Vulgaris) 9 g or Abalone Shell (Shijueming, Haliotidis
Concha) 6 g was added. If constipation was identified, Rhubarb Root and Rhizome (Dahuang, Radix Et Rhizoma Rhei)
6 g was added. If deficiency of yin was identified, Ningpo Figwort Root (Xuanshen, Radix Scrophulariae Ningpoensis)
9 g was added.
LDXGD, longdanxiegan decoction.
Primary Outcome Measure
In this study, BP including SBP, DBP, and categorical BP
was defined as primary outcome measure. All of the included
trials reported the efficacy of LDXGD on BP. Continuous BP
was reported in 3 trials (Ye, 2013; Li, 2014, 2015), while
categorical BP in 6 trials (Yu and Ma, 2004; He and Wang,
2010; Cao et al., 2014; Chen et al., 2014; Xu, 2014; Ma,
2015). For categorical BP, China Food and Drug Administration
recommended the evaluation criteria as below: “significant
improvement” (DBP decreased by 10 mmHg, reaching the
normal range, or DBP not returning to normal but reduced
by more than 20 mmHg), “improvement” (DBP decreased
by less than 10 mmHg but reaching the normal range, DBP
decreased by 10 to 19 mmHg but not reaching the normal
range, or SBP decreased by more than 30 mmHg), and
“no improvement” (not meeting the above standards). Both
“significant improvement” and “improvement” were considered
to be “effective,” and “no improvement” was considered to be
“ineffective.”
Six trials with 647 hypertensive patients that compared LPAD
with antihypertensive drugs were identified in this analysis (Ye,
2013; Cao et al., 2014; Chen et al., 2014; Xu, 2014; Li, 2015; Ma,
2015). All data were pooled and significant lowering effects of
LPAD on SBP (n = 138; MD = −4.82 mmHg; 95% CI: −7.89
to −1.76; P = 0.002; Figure 2A), DBP (n = 138; MD = −2.42
mmHg; 95% CI: −3.22 to −1.62; P < 0.00001; Figure 2B),
and categorical BP (n = 509; RR: 1.26; 95% CI: 1.17 to 1.36;
P < 0.00001; Figure 2C) were identified when compared to
antihypertensive drugs.
Three trials with 216 hypertensive patients that compared
LDXGD with antihypertensive drugs were identified in this
analysis (Yu and Ma, 2004; He and Wang, 2010; Li, 2014). A
significant reduction favored LDXGD in SBP (n = 96; reduced
by 5.20 mmHg) and DBP (n = 96; reduced by 3.60 mmHg) were
identified when compared to antihypertensive drugs. But there
was no difference between LDXGD and antihypertensive drugs
used alone on categorical BP (n= 120; RR: 1.09; 95% CI: 0.96 to
1.23; P = 0.18; Figure 3).
Secondary Outcome Measures
The secondary outcomes including mortality, progression to
severe complications, symptoms, HR, TC, and TG were reported
in 8 trials (Yu and Ma, 2004; He and Wang, 2010; Ye, 2013; Cao
et al., 2014; Chen et al., 2014; Xu, 2014; Li, 2015; Ma, 2015).
No study have reported any data on mortality or progression
to severe complications. Symptoms were reported in 6 trials (Yu
and Ma, 2004; He and Wang, 2010; Cao et al., 2014; Chen et al.,
2014; Xu, 2014; Ma, 2015). Four trials with 509 hypertensive
patients that compared LPAD with antihypertensive drugs were
identified in this analysis (Cao et al., 2014; Chen et al., 2014;
Xu, 2014; Ma, 2015). It was identified that improvement in
symptoms was greater for LPAD than antihypertensive drugs
used alone (n = 509; RR: 1.31; 95% CI: 1.15 to 1.49; P < 0.0001;
Figure 4A). Two trials with 120 hypertensive patients that
compared LDXGD with antihypertensive drugs were identified
in this analysis (Yu and Ma, 2004; He and Wang, 2010). Meta-
analysis showed that symptoms were significantly improved by
LDXGD (n = 120; RR: 1.36; 95% CI: 1.13 to 1.64; P = 0.001;
Figure 4B).
HR, TC, and TG were all reported in 2 trials that compared
LPAD with antihypertensive drugs (Ye, 2013; Li, 2015). It was
identified that reduction in HR was greater for LPAD than
antihypertensive drugs used alone (n = 138; MD = −2.40 bpm;
95% CI: −4.23 to −0.56; P = 0.01; Figure 5A). However, no
significant difference between LPAD and antihypertensive drugs
on TC (n = 138; MD = −0.11 mmol/l; 95% CI: −0.65 to 0.44;
P = 0.71; Figure 5B) and TG (n = 138; MD = −0.20 mmol/l;
95% CI:−0.46 to 0.07; P = 0.14; Figure 5C) was identified.
Adverse Effects
Adverse effects were reported in 3 trials (Yu and Ma, 2004;
He and Wang, 2010; Li, 2014). No adverse effects of LDXGD
was identified in 2 trials (Yu and Ma, 2004; Li, 2014). Only
1 trial reported diarrhea in the LDXGD treatment group (He
and Wang, 2010). However, all of these 3 trials reported adverse
effects of the antihypertensive drugs groups, including headache,
facial flushing, palpitation, drowsiness, and fatigue. All of these
adverse effects were not severe. No serious adverse effects were
reported. Meta-analysis suggested that LDXGD was more likely
to have less adverse effects than the antihypertensive drugs used
alone (n = 156; RR: 0.16; 95% CI: 0.03 to 0.89; P = 0.04;
Figure 6). As most of the included trials did not report any
information on adverse effects, the safety of LDXGD is still
unclear.
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FIGURE 2 | Forest plots of the comparison of LPAD vs. antihypertensive drugs for the outcomes of BP: (A) SBP, (B) DBP, and (C) BP. AD, antihypertensive drugs; BP,
blood pressure; DBP, diastolic blood pressure; LPAD, longdanxiegan decoction plus antihypertensive drugs; SBP, systolic blood pressure.
FIGURE 3 | Forest plots of the comparison of LDXGD vs. antihypertensive drugs for the outcomes of BP. AD, antihypertensive drugs; BP, blood pressure; LDXGD,
longdanxiegan decoction.
Evaluation of Publication Bias
Because the number of included trials was too small (less than
10), it was impossible to conduct a sufficient additional analysis
of publication bias.
DISCUSSION
Summary of Evidence
TCM classic herbal formulas have been recommended as
complementary and alternative regimens for hypertension
treatment in China and other countries (Xiong et al., 2013c,
2017b; Xiong, 2015). Due to concerns about the long term
medication and adverse effects of the antihypertensive drugs,
some mild to moderate hypertensive patients who are not
willing to take antihypertensive drugs will give priority to herbal
medicine including LDXGD either used alone or in combination
with antihypertensive drugs. In their opinion, LDXGD could
improve symptoms, reduce BP fluctuation, and then reduce
the amount of conventional western medicine in spite of its
bitter and slightly sweet taste. In addition, as it has been used
for hundreds of years, LDXGD seems to be relatively safe.
However, the efficacy and safety of LDXGD on hypertension
is still not well-known. In this study, both LDXGD original
prescription and modified LDXGD were enrolled. From the
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FIGURE 4 | Forest plots of the efficacy of LPAD for the outcome of symptoms. AD, antihypertensive drugs; LDXGD, longdanxiegan decoction; LPAD, longdanxiegan
decoction plus antihypertensive drugs. (A) symptoms: LPAD vs. antihypertensive drugs. (B) symptoms: LDXGD vs. antihypertensive drugs.
FIGURE 5 | Forest plots of the comparison of LPAD vs. antihypertensive drugs for the outcomes of (A) HR, (B) TC, and (C) TG. AD, antihypertensive drugs; HR, heart
rate; LPAD, longdanxiegan decoction plus antihypertensive drugs; TC, total cholesterol; TG, triglycerides.
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FIGURE 6 | Forest plot of the reported adverse effects. AD, antihypertensive drugs; LDXGD, longdanxiegan decoction.
TCM physicians’ viewpoint, each TCM classic herbal formula
including LDXGD, is considered to be an independent “unit.”
That is to say, the drug composition and efficacy of LDXGD
are fixed. However, LDXGD could be modified based on the
chief complaint and accompanying symptoms of the patients
when seeing a doctor on the basis of syndrome differentiation
and personalized treatment principle. As Chinese Gentian
Root (Longdancao, Radix Gentianae Longdancao) is one of
the most critical herb in LDXGD (also named “Jun” herb
in TCM), it can’t be removed when modifying the formula.
However, some herbs beside Chinese Gentian Root (Longdancao,
Radix Gentianae Longdancao) in LDXGD could be removed
when it is no longer needed. On the other hand, other
herbs could also be added into LDXGD when it is needed.
With the similar composition and pharmacological effects,
all of them can be considered to be the same category of
LDXGD.
Our primary finding was that LDXGD either used alone
or as adjuctive therapy resulted in a statistically significant
reduction in BP. As we know, lowering BP is the cornerstone
for the treatment of hypertension. In this review, LPAD
significantly improved SBP (MD = −4.82 mmHg; 95% CI:
−7.89 to −1.76; P = 0.002) and DBP (MD = −2.42
mmHg; 95% CI: −3.22 to −1.62; P < 0.00001), compared
with antihypertensive drugs; when used alone, LDXGD also
significantly improved SBP (reduced by 5.20 mmHg) and DBP
(reduced by 3.60mmHg), compared with antihypertensive drugs.
Although the magnitude of BP reduction is small, LDXGD
could be used as complementary and alternative approach for
hypertensive patients, especially if they are partially insensitive
to the antihypertensive drugs treatment alone and have poor
compliance.
The second finding of this paper was that LDXGD
significantly improve hypertension related symptoms. Vertigo
and headache are common symptoms of hypertension. Although
the elevated BP can be well-controlled by antihypertensive drugs,
these symptoms still troubled partially hypertensive patients.
Therefore, they hope to find a better therapeutic modality to
improve their symptoms. In this study, LDXGD either used alone
(RR: 1.36; 95% CI: 1.13 to 1.64; P = 0.001) or in combination
with antihypertensive drugs (RR: 1.31; 95% CI: 1.15 to 1.49;
P < 0.0001) could relieve discomfort in hypertensive patients. It
suggested that LDXGD may be suitable for hypertensive patients
with uncontrolled symptoms.
The third finding of this meta-analysis was the efficacy of
LDXGD on HR and blood lipids. HR is an important factor
in the formation process of hypertension. Lowering HR could
contribute to the treatment of hypertension. Although HR
was significantly reduced by LDXGD treatment (MD = −2.40
bpm; 95% CI: −4.23 to −0.56; P = 0.01), it should be
considered with caution considering the intensity was so mild.
Additionally, LDXGD as adjuctive therapy also produced a
clinically meaningful, but not statistically significant, reduction
in TC (MD = −0.11 mmol/l; 95% CI: −0.65 to 0.44; P = 0.71)
and TG (MD=−0.20 mmol/l; 95% CI:−0.46 to 0.07; P = 0.14).
Limitations for the Review
There are still some limitations in this review that should
be considered before accepting the findings. Firstly, the
methodological quality of the included trials was assessed to be
generally poor based on the Cochrane handbook. Essentially,
no well-designed RCTs with high quality could be identified.
Secondly, information recording the efficacy of LDXGDonmajor
cardiovascular events is lacking. Therefore, whether a long-term
protective effect existed is still unknown. Thirdly, the relationship
between the dosage and course and BP-lowering effect of
LDXGD could not be determined in this study. Fourthly, as no
more detailed information on washout period and measurement
method of BP by trained clinical personnel could be identified
and short treatment duration to see antihypertensive effect in
some trials, the efficacy of LDXGD on BP should be considered
with caution. Fifthly, as RCTs published in China are more
inclined to report positive results in both symptoms and serious
adverse effects, the potential reporting bias can’t be ignored.
Sixthly, conclusions about the safety of LDXGD is still unclear
as only 3 trials reported data on adverse effects.
CONCLUSION
In summary, GRADE approach was used to assess the quality
of LDXGD for hypertension in this study. However, the quality
level of evidence was rated to be low considering the risk of
bias (degraded by 2 levels), as well as potential publication
bias. Therefore, due to poor methodological quality of the
included trials, as well as potential reporting bias, our review
found no conclusive evidence for the effectiveness of LDXGD in
treating hypertension. The potential beneficial effects and safety
of LDXGD should be assessed in future properly designed trials in
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compliance with the CONSORT Statement (Gagnier et al., 2006;
Schulz et al., 2012).
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